BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 16, 2008
View Archived Issues
XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial
Read More
Genentech Earnings Just OK, 'Flattish' 2008 Ahead: Analyst
Read More
Pervasis Gets $9.75M to Boost Blood Vessel Repair Candidate
Read More
Alfacell Deals U.S. Rights for Onconase to Strativa
Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today)
Read More
Novo Nordisk Halts Development of its Inhaled Insulin Program
Read More
Clinic Roundup
Read More
Other News To Note
Read More